✦ LIBER ✦

SCH 503034, a Novel Hepatitis C Virus Protease Inhibitor, Plus Pegylated Interferon α-2b for Genotype 1 Nonresponders

✍ Scribed by Christoph Sarrazin; Regine Rouzier; Frank Wagner; Nicole Forestier; Dominique Larrey; Samir K. Gupta; Musaddeq Hussain; Amrik Shah; David Cutler; Jenny Zhang; Stefan Zeuzem

Book ID: 119759673
Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 587 KB
Volume: 132
Category: Article
ISSN: 0016-5085
DOI: 10.1053/j.gastro.2007.01.041

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pegylated α-interferon-2a plus ribavirin

Pegylated α-interferon-2a plus ribavirin compared with pegylated α-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: Prospective, non-randomized study

✍ Amparo Escudero; Felicidad Rodríguez; Miguel A Serra; Juan A Del Olmo; Francisco 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 150 KB

Generalised Dermatitis Induced by Pegyla

Generalised Dermatitis Induced by Pegylated Interferon-α-2b in a Patient Infected with Genotype-1 Hepatitis C Virus

✍ Dr L. Gallelli, M. Ferraro, G. F. Mauro, G. De Sarro 📂 Article 📅 2005 🏛 Springer International Publishing AG 🌐 English ⚖ 277 KB

Serum PAI-1 is a novel predictor for res

Serum PAI-1 is a novel predictor for response to pegylated interferon-α-2b plus ribavirin therapy in chronic hepatitis C virus infection

✍ D. Miki; W. Ohishi; H. Ochi; C. N. Hayes; H. Abe; M. Tsuge; M. Imamura; N. Kamat 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 114 KB

High-Dose Interferon-α2b Plus Ribavirin

High-Dose Interferon-α2b Plus Ribavirin for Retreatment of Interferon-Nonresponsive Patients Infected with Genotype 1 Hepatitis C Virus

✍ Maria Buti; Sergio Morral; Francisco Sanchez; Maria Martell; Carlos Stalgis; R. 📂 Article 📅 2001 🏛 Springer US 🌐 English ⚖ 68 KB

Dose comparison study of pegylated inter

Dose comparison study of pegylated interferon-α-2b plus ribavirin in naïve Japanese patients with hepatitis C virus genotype 2: A randomized clinical trial

✍ Tomokazu Kawaoka; Yoshiiku Kawakami; Keiji Tsuji; Hiroyuki Ito; Mikiya Kitamoto; 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 162 KB

Favorable factors for re-treatment with

Favorable factors for re-treatment with pegylated interferon α2a plus ribavirin in patients with high viral loads of genotype 1 hepatitis C virus

✍ Akihiro Tamori; Kiyohide Kioka; Osamu Kurai; Hiroki Sakaguchi; Masaru Enomoto; H 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 543 KB